Search

Amgen Inc

Închisă

SectorSănătate

409.97 4.27

Rezumat

Modificarea prețului

24h

Curent

Minim

379.52

Maxim

394.43

Indicatori cheie

By Trading Economics

Venit

-3.6B

-1.8B

Vânzări

1.4B

10B

P/E

Medie Sector

23.681

56.432

EPS

6.29

Randament dividend

2.6

Marjă de profit

-18.092

Angajați

31,500

EBITDA

-416M

3.4B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+3.39% upside

Dividende

By Acuity

Randament dividend

Medie Sector

2.60%

2.27%

Următoarele câștiguri

3 nov. 2026

Data viitoare de dividende

11 dec. 2026

Următoarea dată ex-dividende

20 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

1.8B

206B

Deschiderea anterioară

405.7

Închiderea anterioară

409.97

Sentimentul știrilor

By Acuity

53%

47%

247 / 339 Clasament în Healthcare

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 sept. 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17 sept. 2026, 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16 sept. 2026, 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15 sept. 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14 sept. 2026, 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11 sept. 2026, 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10 sept. 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8 sept. 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 sept. 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 sept. 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 sept. 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1 sept. 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31 aug. 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28 aug. 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27 aug. 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26 aug. 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25 aug. 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24 aug. 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21 aug. 2026, 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20 aug. 2026, 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19 aug. 2026, 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18 aug. 2026, 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17 aug. 2026, 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14 aug. 2026, 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13 aug. 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12 aug. 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11 aug. 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7 aug. 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6 aug. 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5 aug. 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

3.39% sus

Prognoză pe 12 luni

Medie 398.727 USD  3.39%

Maxim 460 USD

Minim 230 USD

În baza a 24 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

24 ratings

9

Cumpărare

13

Păstrare

2

Vânzare

Sentiment

By Acuity

247 / 339 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.